| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
55,060,000 |
| Market
Cap: |
7.54(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$76.73 - $187.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Masimo is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions. Co.'s main business is Measure-through Motion and Low Perfusion™ pulse oximetry. Co.'s products offerings also include noninvasive monitoring of blood constituents with an optical signature, optical oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring, exhaled gas monitoring, nasal high flow ventilation, minimally invasive neuromodulation technology for pain and addiction reduction, hospital automation and connectivity solutions and home wellness and monitoring.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
6,365 |
53,183 |
| Total Buy Value |
$0 |
$0 |
$1,000,342 |
$6,992,959 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
4 |
| Total Shares Sold |
40,000 |
40,000 |
40,000 |
40,000 |
| Total Sell Value |
$5,446,616 |
$5,446,616 |
$5,446,616 |
$5,446,616 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-02-06 |
4 |
AS |
$176.04 |
$232,901 |
D/D |
(1,323) |
6,264 |
|
28% |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-02-06 |
4 |
OE |
$19.72 |
$26,090 |
D/D |
1,323 |
7,587 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-02-05 |
4 |
AS |
$176.50 |
$1,319,720 |
D/D |
(7,477) |
6,264 |
|
27% |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-02-05 |
4 |
OE |
$19.72 |
$147,446 |
D/D |
7,477 |
13,741 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-02-04 |
4 |
AS |
$176.01 |
$211,212 |
D/D |
(1,200) |
6,264 |
|
28% |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-02-04 |
4 |
OE |
$19.72 |
$23,664 |
D/D |
1,200 |
7,464 |
|
- |
|
| Barker Steven |
Director |
– • – |
2020-01-22 |
4 |
AS |
$175.00 |
$1,750,001 |
D/D |
(10,000) |
66,245 |
|
37% |
|
| Barker Steven |
Director |
– • – |
2020-01-22 |
4 |
OE |
$28.03 |
$280,300 |
D/D |
10,000 |
76,245 |
|
- |
|
| Young Micah W |
EVP & Chief Financial Officer |
• – – |
2020-01-17 |
4 |
AS |
$170.06 |
$271,932 |
D/D |
(1,599) |
0 |
|
39% |
|
| Young Micah W |
EVP & Chief Financial Officer |
• – – |
2020-01-17 |
4 |
OE |
$84.97 |
$135,867 |
D/D |
1,599 |
1,599 |
|
- |
|
| Young Micah W |
EVP & Chief Financial Officer |
• – – |
2020-01-16 |
4 |
AS |
$170.01 |
$1,428,233 |
D/D |
(8,401) |
0 |
|
38% |
|
| Young Micah W |
EVP & Chief Financial Officer |
• – – |
2020-01-16 |
4 |
OE |
$84.97 |
$713,833 |
D/D |
8,401 |
8,401 |
|
- |
|
| Coleman Jon |
Pres-WW Sales,Pro Svc,Med Affs |
• – – |
2020-01-02 |
4 |
D |
$158.58 |
$116,715 |
D/D |
(736) |
12,465 |
|
- |
|
| Coleman Jon |
Pres-WW Sales,Pro Svc,Med Affs |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
13,201 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-01-02 |
4 |
D |
$158.58 |
$116,715 |
D/D |
(736) |
6,264 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
7,000 |
|
- |
|
| Lee Yongsam |
EVP & CIO |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
75,000 |
|
- |
|
| Kiani Joe E |
CEO and Chairman of the Board |
• • – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
159,241 |
|
- |
|
| Sampath Anand |
EVP, Ops & Clinical Research |
• – – |
2020-01-02 |
4 |
D |
$158.58 |
$116,715 |
D/D |
(736) |
13,782 |
|
- |
|
| Sampath Anand |
EVP, Ops & Clinical Research |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
14,518 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2019-12-20 |
4 |
AS |
$159.02 |
$1,257,441 |
D/D |
(7,907) |
5,000 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2019-12-20 |
4 |
OE |
$19.72 |
$158,357 |
D/D |
7,907 |
12,000 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2019-12-19 |
4 |
AS |
$159.29 |
$79,644 |
D/D |
(500) |
5,000 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2019-12-19 |
4 |
OE |
$22.40 |
$11,200 |
D/D |
500 |
5,500 |
|
- |
|
| Mcclenahan Thomas Samuel |
EVP & General Counsel |
• – – |
2019-12-18 |
4 |
AS |
$159.00 |
$156,775 |
D/D |
(986) |
5,000 |
|
- |
|
863 Records found
|
|
Page 9 of 35 |
|
|
0.75 (0.55%) 
